|
ATK
Ahmedabad (Gujarat) [India], May 13: Human Biosciences Inc., a leading US-based pharmaceutical firm, has joined forces with Kenyan company Skintech Green Ltd to introduce cutting-edge collagen products for wound treatment in Kenyan hospitals. The collaboration aims to enhance healthcare in the country while fostering economic growth through the establishment of a multi-million shilling production plant within the next two years, setting up the opportunity to employ hundreds of health experts directly and indirectly. Dr. Gerhard Goebel, International Business Development Officer at Human Biosciences, recently visited Eldoret to discuss transformative plans and begin educating medical professionals."Every month, thousands of patients visit hospitals for treatment of skin injuries. Our collagen products can cut the healing period in half, reducing treatment costs and resources. This will pave the way for massive changes in Kenyan healthcare and socio-economic development overall." Human Biosciences, Inc. boasts a successful track record, collaborating with over 6,000 hospitals across the United States and globally. The company's strategic objective is to introduce its revolutionary collagen products worldwide, with partnerships in Germany, Taiwan and India to date. This plant will position Kenya as a pioneer in Africa with state-of-the-art production and substantial growth in the local economy. Collagen, a vital protein abundant in skin, bones, tissues, and tendons, plays a crucial role in providing strength and structure to promote healing in open wounds of all causes. The Director of Skintech, Dr. John Kibosia, highlighted the positive impact the plant would have on the livestock sector: "The Collagen production process involves sourcing hides from local farmers, which will provide vital support to the agricultural community. This initiative demonstrates a commitment to corporate social responsibility and sustainable practices." The collaboration between Human Biosciences, Inc. and Skintech Green Ltd signifies a groundbreaking partnership poised to elevate Kenya's healthcare standards. As the companies embark on this transformative journey, they have already begun meeting with members of the medical community to begin the process of educational development prior to the rollout of available products. For supplies and purchasing information contact: india-info@humanbiosciences.com About Human BioSciences Human BioSciences Inc. is a global biotechnology company specializing in collagen-based products for wound care management. Dr Manoj Jain founded HBS in 1990 with Kollagen technology, pioneering advanced wound care with native non-hydrolyzed Type -1 bovine collagen in its purest form with three delivery modes with SkinTemp II Collagen Sheets, Medifil II Collagen Particles and Collatek Collagen Gel. HBS continues engineering breakthroughs daily with innovative new product development, manufacturing advancements, and global product distribution with facilities in the USA and India. For more information, visit: www.humanbiosciences.com (ADVERTORIAL DISCLAIMER: The above press release has been provided by ATK. ANI will not be responsible in any way for the content of the same)
|
